{rfName}
Ax

Indexed in

License and Use

Icono OpenAccess

Altmetrics

Analysis of institutional authors

Ortiz-Maldonado, ValentinAuthor

Share

March 13, 2025
Publications
>
Article

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

Publicated to: Haematologica. 108 (1): 110-121 - 2023-01-01 108(1), DOI: 10.3324/haematol.2022.280805

Authors: Kwon, M; Iacoboni, G; Reguera, JL; Corral, LL; Morales, RH; Ortiz-Maldonado, V; Guerreiro, M; Caballero, AC; Domínguez, MLG; Pina, JMS; Mussetti, A; Sancho, JM; Bastos-Oreiro, M; Catala, E; Delgado, J; Henriquez, HL; Sanz, J; Calbacho, M; Bailén, R; Carpio, C; Ribera, JM; Sureda, A; Briones, J; Hernandez-Boluda, JC; Cebrián, NM; Martin, JLD; Martín, A; Barba, P

Affiliations

5.07.02 - Neoplàsies limfoides. Institut d'Investigacions Biomèdiques August Pi i Sunyer - Author
Hosp Badalona Germans Trias & Pujol, Josep Carreras Res Inst, Inst Catalan Oncol, Dept Hematol, Badalona, Spain - Author
Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain - Author
Hosp Clin Univ Salamanca, Dept Hematol, IBSAL, Salamanca, Spain - Author
Hosp Clin Univ Valencia, Inst Invest Sanitaria INCL, Dept Hematol, Valencia, Spain - Author
Hosp Duran & Reynals, Inst Catalan Oncol, Dept Hematol, Barcelona, Spain - Author
Hosp Gen Univ Gregorio Maranon, Dept Hematol, Madrid, Spain - Author
Hosp Santa Creu & Sant Pau, Dept Hematol, Barcelona, Spain - Author
Hosp Univ & Politecn La Fe, Dept Hematol, Valencia, Spain - Author
Hosp Univ 12 Octubre, Dept Hematol, Madrid, Spain - Author
Hosp Univ Gran Canaria Doctor Negrin, Dept Hematol, Las Palmas Gran Canaria, Spain - Author
Hosp Univ Virgen Rocio, Inst Biomed Sevilla, Dept Hematol, Seville, Spain - Author
Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain - Author
Univ Autonoma Barcelona, Dept Med, Bellaterra, Spain - Author
Univ Complutense Madrid, Madrid, Spain - Author
Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Dept Hematol, Expt Hematol, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain - Author
See more

Abstract

Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety and efficacy of axi-cel and tisa-cel outside the setting of a clinical trial. Data from consecutive patients with R/R LBCL who underwent apheresis for axi-cel or tisa-cel were retrospectively collected from 12 Spanish centers. A total of 307 patients underwent apheresis for axi-cel (n=152) and tisa-cel (n=155) from November 2018 to August 2021, of which 261 (85%) received a CAR T infusion (88% and 82%, respectively). Median time from apheresis to infusion was 41 days for axi-cel and 52 days for tisa-cel (P=0.006). None of the baseline characteristics were significantly different between both cohorts. Both cytokine release syndrome and neurologic events (NE) were more frequent in the axi-cel group (88% vs. 73%, P=0.003, and 42% vs. 16%, P= 2 and progressive disease before lympho-depletion. Safety and efficacy results in our real-world experience were comparable with those reported in the pivotal trials. Patients treated with axi-cel experienced more toxicity but similar non-relapse mortality compared with those re-ceiving tisa-cel. Efficacy was not significantly different between both products.

Keywords

Adaptor proteins, signal transducingAdoptive immunotherapyAdultAdverse eventAgedAggressive b cell lymphomaAnakinraAntigens, cd19ArticleAxicabtagene ciloleucelB cell lymphomaCancer mortalityCd19 antigenChimeric antigen receptor t-cell immunotherapyCohort analysisCyclophosphamideCytokine release syndromeDexamethasoneDiffuse large b cell lymphomaDrug efficacyDrug safetyEcog performance statusFemaleFludarabineFollow upHumanHumansImmune effector cell associated neurotoxicity syndromeImmunotherapy, adoptiveInfectionLactate dehydrogenaseLactate dehydrogenase aLymphoma, large b-cell, diffuseMaleNeurotoxicityNeutropeniaNon relapse mortalityOutcomesOverall survivalPositron emission tomography-computed tomographyProgression free survivalReal-worldRetrospective studiesRetrospective studyRevised international prognostic indexSignal transducing adaptor proteinSiltuximabSteroidTherapyThrombocytopeniaTisagenlecleucelTisagenlecleucel tTocilizumab

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Haematologica due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2023, it was in position 11/97, thus managing to position itself as a Q1 (Primer Cuartil), in the category Hematology.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 19.5. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 13, 2025)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 14.84 (source consulted: FECYT Mar 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-12-15, the following number of citations:

  • WoS: 93
  • Scopus: 95

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-12-15:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 66.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 66 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 41.
  • The number of mentions on the social network X (formerly Twitter): 39 (Altmetric).
  • The number of mentions in news outlets: 2 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Awards linked to the item

Funding PS has received funding funding from the Carlos III (FIS) Health Institute PI16/01433 and PI21/00197, Asociacion Es-panola contra el Cancer (Ideas Semilla 2019) and a PERIS 2018-2020 grant from the Generalitat de Catalunya (BDNS357800) .